Stakeholder Perceptions of the Use of Mobile Technology in Clinical Trials
Adoption of mobile technology use in clinical trials relies on positive reception from key stakeholders; yet, little is known about the possible barriers and facilitators of its use from the perspectives of clinical investigators and trial participants. Early evidence-gathering activities conducted by CTTI suggest that key stakeholders may be more engaged in clinical trials when mobile technology is used; therefore, it is important to ensure their needs and concerns with using mobile technology are met.
The goal of this project within CTTI’s MCT Program is to propose recommendations to overcome barriers to the use of mobile technology in clinical trials as perceived by key stakeholders, including site investigators and potential research participants. The scope of the program includes use of mobile technology in FDA-regulated clinical trials after the time of participant consent.
CLICK HERE to read more about the MCT Program.
Understanding key stakeholders’ familiarity with mobile technology as well as their concerns with using such technology is critical to ensuring their adherence to the technology and limiting the burden of participation in clinical trials. Currently, information is sparse on how stakeholders feel about the use of mobile technologies within clinical trials; therefore, CTTI plans to explore the perceptions of key stakeholders regarding its use to allow for the identification of strategies for overcoming barriers.
Mobile Clinical Trials Program: Patient, Caregiver, Investigator and Provider Perceptions of the Use of Mobile Technology in Clinical Trials (2015 – ongoing)
CLICK HERE to view other projects within CTTI’s MCT Program.
Among potential research participants:
Among site investigators who have been involved in mobile clinical trials:
Results from this project will encourage high-quality, efficient trials that successfully leverage the use of mobile technology in ways that incorporate the needs and expectations of potential research participants and site investigators.
|Team Member||Amanda Niskar||Individual Patient/Caregiver|
|Social Science Lead||Amy Corneli||CTTI|
|Team Member||Angie Botto-van Bemden||Arthritis Foundation|
|Team Member||Annick Anderson*||CISCRP|
|Team Leader||Cindy Geoghegan||Individual Patient/Caregiver|
|Team Member||Dave Borasky||WIRB-Copernicus IRB|
|Team Member||David Brennan*||Medstar Health Research Institute|
|Team Member||Guy Eakin*||Arthritis Foundation|
|Team Member||Hassan Kadhim||Boehringer Ingelheim|
|Team Member||Ido Paz-Priel||Genentech - A Member of the Roche Group|
|Team Member||Immo Zadezensky*||US Food and Drug Administration|
|Team Member||Junyang Wang||US Food and Drug Administration|
|Team Member||Kara Dennis||Medidata Solutions|
|Team Member||Ken Skodacek||US Food and Drug Administration|
|Team Member||Kristine Nelson*||EMMES|
|Team Member||Les Jordan||Target Health|
|Team Member||Maria Ali||The George Institute|
|Team Member||Petros Okubagzi||Medstar Health Research Institute|
|Team Member||Ricky Bloomfield*||Duke University|
|Team Leader||Steve Morin||US Food and Drug Administration|
|Team Member||Sue Dubman||Individual Patient/Caregiver|
|Team Member||Terri Hinkley*||Association of Clinical Research Professionals|
|Executive Committee Champion & Team Leader||Virginia Nido||Genentech - A Member of the Roche Group|
|Team Leader||William Wood||University of North Carolina-Chapel Hill|
|Project Manager||Zach Hallinan||CTTI|